Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA CA 25 004

Opportunity Information: Apply for RFA CA 25 004

The National Cancer Institute (NCI) is offering this grant opportunity, RFA-CA-25-004, titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." It is a discretionary NIH grant in the health and education activity area (CFDA 93.394) and sits within NCI's broader Innovative Molecular Analysis Technologies (IMAT) Program. The overall intent is to move promising biospecimen-related technologies past the early proof-of-concept stage and into a more mature, rigorously validated state so they can be used more confidently in cancer research and, where appropriate, clinical care workflows.

The focus is specifically on technologies that improve how cancer-relevant biospecimens and their derivatives are collected, handled, processed, preserved, and stored. NCI is looking for practical tools, devices, assays, and companion methods that reduce the kinds of errors and variability introduced before an actual measurement is made, meaning the pre-analytical phase where samples can degrade, be contaminated, or otherwise change in ways that distort downstream results. A strong fit for this program would be a technology that either better preserves or protects sample integrity (for example, stabilizing fragile analytes) or that establishes clearer verification criteria and quality assessment/quality control approaches so researchers and clinicians can determine whether a given specimen is truly fit for the intended molecular or cellular analysis.

This is not an early feasibility program. Applicants are expected to have already addressed the major feasibility gaps and to provide supportive preliminary data showing the core concept works. What NCI wants to fund here is the next step: further development, optimization, and especially rigorous validation. In practice, that means demonstrating performance characteristics that matter for real-world use, such as reproducibility, robustness across operators or sites, sensitivity to common handling variations, and the ability to reduce or at least measure pre-analytical degradation of targeted analytes. The end goal is to deliver technologies that are ready to accelerate and strengthen cancer biology studies, early detection and screening research, clinical diagnosis, treatment-related research, and epidemiology, while also being relevant to issues that contribute to cancer health disparities (for example, enabling higher-quality sampling in low-resource or decentralized settings, or reducing bias introduced by uneven specimen handling across populations and sites).

The NOFO explicitly states that clinical trials are not allowed under this mechanism, signaling that the work should stay in the development and validation lane rather than testing interventions in human participants as clinical outcomes trials. The supported projects are exploratory in the sense that they are still advancing an emerging approach, but they should be grounded in data and aimed at producing convincing validation evidence rather than speculative concepts.

Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants listed include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized governments); public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities. The NOFO also highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-domestic (non-U.S.) entities, reflecting an intent to encourage broad participation and potentially support technologies that can be deployed across diverse settings.

Key logistics included in the source information are an original application closing date of 2025-10-03, an award ceiling of $300,000, and an expectation of approximately 2 awards. The opportunity was created on 2024-12-16. Taken together, this NOFO is essentially asking applicants to bring forward biospecimen science technologies that already have a credible foundation, then use R33 support to finish the engineering and method development work and produce the kind of rigorous validation package that convinces the field the technology can reliably improve specimen quality, reduce pre-analytical artifacts, and enable stronger, more equitable cancer research and translational applications.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on 2024-12-16.
• Applicants must submit their applications by 2025-10-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $300,000.00 in funding.
• The number of recipients for this funding is limited to 2 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 25 004

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: